Journal of Clinical Immunology

, Volume 10, Issue 1, pp 52–60 | Cite as

Normal mitogen-induced suppression of the interleukin-6 (IL-6) response and its deficiency in systemic lupus erythematosus

  • Richard J. Warrington
  • W. John Rutherford
Original Articles

Abstract

A low-frequency suppressor-cell population in normal peripheral blood inhibits the B-cell CESS response to IL-6, following pokeweed mitogen stimulation. The suppression of IL-6 responsiveness is (i) radiation sensitive, (ii) directed against CESS targets and not mediated by inhibition of IL-6 production, and (iii) associated with nonspecific cytotoxic activity against CESS targets. The generation of these cytolytic cells is also radiation sensitive. A correlation was found between PWM-induced cytotoxicity against CESS and the suppression of IL-6-dependent IgG production. But cytotoxicity toward CESS targets is not responsible for this suppression because (i) IL-2 induces equivalent or greater nonspecific cytotoxicity against CESS in the total absence of suppression of CESS-derived IgG production and (ii) suppression is also induced by mitogen-activated PBL separated from CESS targets by a cell-impermeable membrane. This suppression was not mediated by TNFα/β or IFN-γ. In systemic lupus erythematosus, suppression of IL-6-dependent IgG production is impaired in patients with active disease (29.2±13.7%) compared to patients with inactive disease (70±19.5%) or normal controls (82.8±9.2%). There is also a defect in mitogen-induced nonspecific cytotoxicity in active SLE (specific lysis 15.1±3.5%, compared to 34±4% in normals). Pokeweed mitogen-activated PBL can therefore normally induce suppression of B-cell IL-6 responses and this response is deficient in lupus.

Key words

Systemic lupus erythematosus (SLE) interleukin-6 (IL-6) suppression 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Warrington RJ: B cell differentiation factor production in systemic lupus erythematosus. J Rheumatol 15:55–58, 1988Google Scholar
  2. 2.
    Brieva JA, Targan S, Stevens RH: NK and T cell subsets regulate antibody production by human in vivo antigen-induced lymphoblastoid B cells. J Immunol 132:611–615, 1984Google Scholar
  3. 3.
    Arai S, Yamamoto H, Itoh K, Kumagi K: Suppressive effect of human natural killer cells on pokeweed mitogen-induced B cell differentiation. J Immunol 131:651–657, 1983Google Scholar
  4. 4.
    Storkus WJ, Dawson JR: B cell sensitivity to Natural Killing: Correlation with target cell stage & differentiation and state of activation. J Immunol 136:1542–1547, 1986Google Scholar
  5. 5.
    Fox EJ, Cook RG, Lewis DE, Rich RR: Proliferative signals for human suppressor cells: Helper cells stimulated with pokeweed mitogen in vitro produce a suppressor growth factor. J Clin Invest 78:214–220, 1986Google Scholar
  6. 6.
    Elmasry MN, Fox EJ, Rich RR: Sequential effects of prostaglandins and interferon-γ on differentiation of CD8+ suppressor cells. J Immunol 139:688–694, 1987Google Scholar
  7. 7.
    Warrington RJ: Interleukin-2 abnormalities in systemic lupus erythematosus and rheumatoid arthritis. A role for overproduction of IL-2 in human autoimmunity. J Rheumatol 15:616–620, 1989Google Scholar
  8. 8.
    Boyum A: Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 21 (Suppl 97):77–89, 1983Google Scholar
  9. 9.
    Wilkins JA, Jordan Y, Rutherford WJ, Warrington RJ: T cell factor-mediated suppression of immunoglobulin secretion by a human B lymphoblastoid cell line. J Immunol 131:298–302, 1983Google Scholar
  10. 10.
    Wilkins JA, Warrington RJ: The production of immunoregulatory factors by a human macrophage-like cell line. III. The relationship of IDS-U937 to human interferons. Cell Immunol 86:354–361, 1984Google Scholar
  11. 11.
    Bolhuis RL, Schuit HRE, Nooyen AM, Rontelup, CPM: Characterization of Natural Killer (NK) cells and Killer (K) cells in human blood: Discrimination between NK and K cell activities. Eur J Immunol 8:731–740, 1978Google Scholar
  12. 12.
    Honda M, Cahn C, Shevach EM: Characterization and partial purification of a specific interleukin 2 inhibitor. J Immunol 135:1834–1839, 1985Google Scholar
  13. 13.
    Tiku K, Tiku ML, Liu S, Skosey JL: Normal human neutrophils are a source of a specific interleukin 1 inhibitor. J Immunol 136:3686–3692, 1986Google Scholar
  14. 14.
    Rayner AA, Grimm EA, Lotze HT, Wilson DT, Rosenberg JA: Lymphokine activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh tumor cells from autologous and multiple allogeneic tumors. J Natl Cancer Inst 75:67–75, 1985Google Scholar
  15. 15.
    Bonavida B, Robins A, Saxon A: Lectin-dependent cellular cytotoxicity in man. Transplantation 23:261–270, 1977Google Scholar
  16. 16.
    Murakawa Y, Takada S, Ueda Y, Suzuki N, Hoshino T, Sakane T: Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus. J Immunol 134:187–195, 1985Google Scholar

Copyright information

© Plenum Publishing Corporation 1990

Authors and Affiliations

  • Richard J. Warrington
    • 1
  • W. John Rutherford
    • 1
  1. 1.Department of Medicine and ImmunologyUniversity of ManitobaWinnipegCanada

Personalised recommendations